<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814329</url>
  </required_header>
  <id_info>
    <org_study_id>2021ZZLX03</org_study_id>
    <nct_id>NCT04814329</nct_id>
  </id_info>
  <brief_title>Glioblastoma Response Prediction to Apatinib</brief_title>
  <official_title>Study on Predicting Response of Recurrent Glioblastoma to Apatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Sanbo Brain Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Sanbo Brain Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-angiogenic therapy is an important treatment strategy for recurrent glioblastoma. Our&#xD;
      previous study provided evidence for a potential benefit of apatinib, a humanized monoclonal&#xD;
      antibody against VEGFR-2, when added to temozolomide chemotherapy in patients with recurrent&#xD;
      glioblastoma. Some patients showed durable responses and prolonged survival, with recorded&#xD;
      survival times of over 30 months in 6.4% patients. However, a subset of patients progressed&#xD;
      in 2 months. There is a strong need to better predict and monitor apatinib treatment response&#xD;
      to prevent patients from adverse effects of ineffective therapy. In this study, whole genome&#xD;
      sequencing and RNA-sequencing of formalin-fixed, paraffin-embedded tumor materials from the&#xD;
      participants who received apatinib and temozolomide treatment will be performed to identify&#xD;
      the response biomarkers and patients who may benefit most from apatinib, avoiding unnecessary&#xD;
      potential toxicity and cost for those who are unlikely to benefit from the drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>genetic outcome</measure>
    <time_frame>up to 2 years</time_frame>
    <description>response prodicting biomarker</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>effective group</arm_group_label>
    <description>After treatment, tumor achieved complete response or partial response and the progression-free survival time was ≥6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stable group</arm_group_label>
    <description>After treatment, tumor remains stable and the progression-free survival time was more than 1 month and less than 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early progressed group</arm_group_label>
    <description>After treatment, tumor got progressed and the progression-free survival time was no more than 1 month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>genetic characteristic</intervention_name>
    <description>the underlying genetic characteristics that prodicting response</description>
    <arm_group_label>Early progressed group</arm_group_label>
    <arm_group_label>effective group</arm_group_label>
    <arm_group_label>stable group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Neuro-oncology Department, Sanbo Bran Hospital Capital Medical University&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70 years old&#xD;
&#xD;
          2. recurrent glioblastoma&#xD;
&#xD;
          3. received apatinib plus temozolomide treatment，response and survival data were&#xD;
             available&#xD;
&#xD;
          4. tumor tissues were acquired&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun-ping Zhang</last_name>
    <phone>86-010-62856783</phone>
    <email>doczhjp@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Capital Medical University Sanbo Brain Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junping Zhang</last_name>
      <phone>86-010-62856783</phone>
      <email>doczhjp@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Sanbo Brain Hospital</investigator_affiliation>
    <investigator_full_name>Junping Zhang</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <keyword>Vascular Endothelial Growth Factor Receptor 2</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

